| 2021 | | Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF- κ B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
| 2018 | | Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study | 김대중, 김혜진, 이관우, 한승진 |
| 2020 | | Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study | 김대중, 하경화 |
| 2017 | | Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data | 김대중, 하경화 |
| 2021 | | Cardiovascular safety of sodium glucose cotransporter 2 inhibitors as add-on to metformin monotherapy in patients with type 2 diabetes mellitus | 김대중, 전자영, 하경화 |
| 2020 | | Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study | 김혜진 |
| 2017 | | Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study | 김대중, 김혜진, 박래웅, 윤덕용, 이관우, 한승진 |
| 2018 | | Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study | 김대중, 김혜진, 이관우, 한승진 |
| 2021 | | Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study | 김대중, 이나미, 하경화, 한승진 |
| 2021 | | Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19 | 김대중 |
| 2019 | | Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study | 김대중, 이기황, 정유리, 하경화 |
| 2017 | | Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) | 이관우 |
| 2023 | | Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | 김대중, 하경화 |
| 2023 | | Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia | 김대중, 하경화 |
| 2023 | | Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study | 김대중, 하경화 |
| 2024 | | Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease | 김대중, 하경화 |
| 2022 | | Healthcare resource utilization in patients treated with empagliflozin in East Asia | 김대중, 하경화 |
| 2017 | | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies | 김대중, 이광재 |
| 2021 | | Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study | 김대중, 하경화 |
| 2016 | | Protective Effects of Dipeptidyl Peptidase-4 Inhibitors on Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes | 이기황, 정유리 |
| 2016 | | Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study | 김대중, 김혜진, 박래웅, 윤덕용, 이관우, 전자영, 한승진 |
| 2020 | | Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study | 김대중 |
| 2021 | | Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study | 정윤석 |
| 2019 | | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study | 김대중, 하경화 |
| 2018 | | Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study | 김대중, 김혜진, 이관우, 전자영, 한승진 |
| 2022 | | Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study | 김대중, 최용준, 하경화 |
